DOCETAXEL MONOTHERAPY COMPARED WITH CARBOPLATIN AND PACLITAXEL DOUBLET CHEMOTHERAPY IN ELDERLY PATIENTS WITH NON-SMALL-CELL LUNG CANCER

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Docetaxel monotherapy (D) is recommended to treat advanced non-small-cell lung cancer (NSCLC) in fit elderly patients in Japan; however, carboplatin and paclitaxel doublet chemotherapy (CP) was also reported to be associated with survival benefits compared with monotherapy. We compared a docetaxel monotherapy regimen with carboplatin and paclitaxel doublet chemotherapy in elderly patients with NSCLC.

Methods

We retrospectively examined overall survival (OS), progression-free survival (PFS) and response rate (RR) in advanced NSCLC patients aged 70 or over who received D alone or CP as a first-line therapy between April 2002 and December 2010 at our institution.

Results

Sixteen patients received D and 39 received CP. The characteristics of the each group were as follows: median age 75 (70–81) and 76.5 (70–84) years; male/female 62/38 and 75/25%; adenocarcinoma/squamous cell carcinoma/undifferentiated carcinoma 54/44/2 and 63/37/0%; PS 0/1/2/3 23/56/13/8 and 31/63/6/0%. The median number of treatment cycles was two in both groups. Antitumor effects were as follows: PR/SD/PD/NE 36/31/25/8 and 25/13/56/6% (P < 0.05); the median PFS 123 (71–175) and 81 (39–123) days; the median OS 456 (268–643) and 585 (48–1122) days. One treatment-related death was observed in the CP group.

Conclusion

Although the RR was higher in the CP group, there were not any differences in PFS and OS between D and CP groups. Both D and CP could be used as a treatment in elderly patients with NSCLC.

Related Topics

    loading  Loading Related Articles